Unaudited Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating activities:
Net loss	$ (15,465,912)	$ (3,997,229)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	19,520	6,154
Loss on sale or disposal of assets	6,761
Stock-based compensation expense	1,121,990	373,989
Common stock issued for advisory services	1,409,363
Abandonment of in-process research and development intangible asset	951,000
Change in deferred income taxes	(364,796)
Settlement of litigation matter	2,500,000
Non-cash interest expense	7,067	160,315
Changes in operating assets and liabilities:
Prepaid expenses, deposits and other assets	50,918	6,652
Accounts payable, accrued expenses and other liabilities	410,014	530,785
Net cash used in operating activities	(9,354,075)	(2,919,334)
Cash flows provided by investing activities:
Purchases of property and equipment	(2,331)	(13,644)
Maturities of certificates of deposit		2,500,000
Cash received in reverse merger transaction	8,500,602
Net cash provided by investing activities	8,498,271	2,486,356
Cash flows provided by financing activities:
Proceeds from the issuance of convertible debt	1,880,000
Net cash provided by financing activities	1,880,000
Net increase (decrease) in cash and cash equivalents	1,024,196	(432,978)
Cash and cash equivalents at beginning of period	1,997,192	2,336,519
Cash and cash equivalents at end of period	3,021,388	1,903,541
Supplemental disclosure of non-cash investing and financing activities:
Conversion of convertible notes and related accrued interest into common stock	711,495	47,742
Consideration in connection with RestorGenex Corporation merger transaction	$ 21,261,000	$ 0